Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
作者信息
Hamada Yukihiro, Tokimatsu Issei, Mikamo Hiroshige, Kimura Masao, Seki Masafumi, Takakura Shunji, Ohmagari Norio, Takahashi Yoshiko, Kasahara Kei, Matsumoto Kazuaki, Okada Kenji, Igarashi Masahiro, Kobayashi Masahiro, Mochizuki Takahiro, Nishi Yoshifumi, Tanigawara Yusuke, Kimura Toshimi, Takesue Yoshio
机构信息
Department of Infection Control and Prevention, Aichi Medical University Graduate School of Medicine, Aichi, Japan.
出版信息
J Infect Chemother. 2013 Jun;19(3):381-92. doi: 10.1007/s10156-013-0607-8. Epub 2013 May 15.
Abstract
摘要
相似文献
1
Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.伏立康唑治疗药物监测实践指南：日本化疗学会和日本治疗药物监测学会的共识性综述
J Infect Chemother. 2013 Jun;19(3):381-92. doi: 10.1007/s10156-013-0607-8. Epub 2013 May 15.
2
Therapeutic drug monitoring of voriconazole in children.伏立康唑的治疗药物监测在儿童中的应用。
Ther Drug Monit. 2012 Feb;34(1):77-84. doi: 10.1097/FTD.0b013e31823f3516.
3
Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.三岁以下儿童伏立康唑的治疗药物监测：一例报告及十例儿童伏立康唑浓度总结。
Pediatr Infect Dis J. 2012 Jun;31(6):632-5. doi: 10.1097/INF.0b013e31824acc33.
4
Therapeutic drug monitoring of voriconazole and posaconazole.伏立康唑和泊沙康唑的治疗药物监测。
Pharmacotherapy. 2011 Feb;31(2):214-25. doi: 10.1592/phco.31.2.214.
5
Rethinking the use of voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.重新思考伏立康唑治疗药物监测在异基因造血干细胞移植受者中的应用。
Bone Marrow Transplant. 2005 Jul;36(2):177. doi: 10.1038/sj.bmt.1705012.
6
Hallucinations during voriconazole therapy: who is at higher risk and could benefit from therapeutic drug monitoring?伏立康唑治疗期间的幻觉：谁的风险更高以及谁能从治疗药物监测中获益？
Ther Drug Monit. 2009 Feb;31(1):135-6. doi: 10.1097/FTD.0b013e3181947901.
7
Voriconazole therapeutic drug monitoring: focus on safety.伏立康唑治疗药物监测：重点关注安全性。
Expert Opin Drug Saf. 2010 Jan;9(1):125-37. doi: 10.1517/14740330903485637.
8
Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.伏立康唑和泊沙康唑治疗侵袭性曲霉病的治疗药物监测。
Expert Rev Anti Infect Ther. 2013 Sep;11(9):931-41. doi: 10.1586/14787210.2013.826989.
9
Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation.对一名患有侵袭性曲霉病且需要体外膜肺氧合的儿童进行伏立康唑治疗药物监测。
Ther Drug Monit. 2008 Dec;30(6):643-6. doi: 10.1097/FTD.0b013e3181898b0c.
10
Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections.奥美拉唑用于提高伏立康唑亚治疗浓度以治疗曲霉菌感染。
Antimicrob Agents Chemother. 2012 Nov;56(11):6001-2. doi: 10.1128/AAC.00700-12. Epub 2012 Aug 13.
引用本文的文献
1
Metagenomic next-generation sequencing enabled diagnosis of spondylitis in an immunocompetent patient: a case report and literature review.宏基因组下一代测序技术助力免疫功能正常患者的脊柱炎诊断：一例病例报告及文献综述
Front Med (Lausanne). 2025 Apr 30;12:1575363. doi: 10.3389/fmed.2025.1575363. eCollection 2025.
2
Evaluation of voriconazole therapeutic drug monitoring in malignant hematology patients.恶性血液病患者伏立康唑治疗药物监测的评估
J Oncol Pharm Pract. 2025 Oct;31(7):1094-1103. doi: 10.1177/10781552241284528. Epub 2024 Sep 19.
3
Associated factors with voriconazole plasma concentration: a systematic review and meta-analysis.伏立康唑血药浓度的相关因素：一项系统评价和荟萃分析。
Front Pharmacol. 2024 Aug 23;15:1368274. doi: 10.3389/fphar.2024.1368274. eCollection 2024.
4
Clinical application of voriconazole in pediatric patients: a systematic review.伏立康唑在儿科患者中的临床应用：系统评价。
Ital J Pediatr. 2024 Jun 9;50(1):113. doi: 10.1186/s13052-024-01684-z.
5
Therapeutic drug monitoring guidelines in oncology: what do we know and how to move forward? Insights from a systematic review.肿瘤学中的治疗药物监测指南：我们了解什么以及如何向前发展？一项系统评价的见解
Ther Adv Med Oncol. 2024 May 27;16:17588359241250130. doi: 10.1177/17588359241250130. eCollection 2024.
6
Comparison of ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and enzyme-multiplied immunoassay technique (EMIT) for quantification of voriconazole plasma concentration from Chinese patients.超高效液相色谱-串联质谱法（UPLC-MS/MS）与酶放大免疫分析技术（EMIT）用于定量中国患者伏立康唑血药浓度的比较
Heliyon. 2023 Nov 13;9(11):e22015. doi: 10.1016/j.heliyon.2023.e22015. eCollection 2023 Nov.
7
The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals.基因多态性和肝功能不全对侵袭性真菌感染患者伏立康唑剂量调整的影响。
Front Genet. 2023 Aug 24;14:1242711. doi: 10.3389/fgene.2023.1242711. eCollection 2023.
8
Status and Quality of Guidelines for Therapeutic Drug Monitoring Based on AGREE II Instrument.基于 AGREE II 工具的治疗药物监测指南的现状和质量。
Clin Pharmacokinet. 2023 Sep;62(9):1201-1217. doi: 10.1007/s40262-023-01283-x. Epub 2023 Jul 25.
9
Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax.基于生理学的药代动力学模型预测伏立康唑和维奈托克药物相互作用的研究进展。
Pharm Res. 2022 Aug;39(8):1921-1933. doi: 10.1007/s11095-022-03289-9. Epub 2022 Jun 21.
10
Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole.药代动力学相关基因多态性和炎症反应对伏立康唑代谢的影响。
Pharmacol Res Perspect. 2022 Apr;10(2):e00935. doi: 10.1002/prp2.935.
本文引用的文献
1
Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.依曲韦林与氟康唑或伏立康唑联合用于 HIV 阴性志愿者的药代动力学和短期安全性。
J Clin Pharmacol. 2013 Jan;53(1):41-50. doi: 10.1177/0091270011433329. Epub 2013 Jan 24.
2
The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.治疗药物监测对侵袭性真菌感染伏立康唑安全性和疗效的影响：一项随机对照试验。
Clin Infect Dis. 2012 Oct;55(8):1080-7. doi: 10.1093/cid/cis599. Epub 2012 Jul 3.
3
Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections.伏立康唑治疗药物监测在侵袭性真菌感染治疗中的作用。
Can J Hosp Pharm. 2009 Nov;62(6):469-82. doi: 10.4212/cjhp.v62i6.845.
4
Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis.伏立康唑血药浓度最佳值的调查与阈：描述性统计荟萃分析。
J Infect Chemother. 2012 Aug;18(4):501-7. doi: 10.1007/s10156-011-0363-6. Epub 2012 Jan 11.
5
Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.比较免疫功能低下儿童和健康成年人伏立康唑静脉-口服转换的药代动力学和安全性。
Antimicrob Agents Chemother. 2011 Dec;55(12):5770-9. doi: 10.1128/AAC.00531-11. Epub 2011 Oct 3.
6
Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.免疫功能低下的青少年与健康成年人中伏立康唑静脉-口服转换的药代动力学和安全性比较。
Antimicrob Agents Chemother. 2011 Dec;55(12):5780-9. doi: 10.1128/AAC.05010-11. Epub 2011 Sep 12.
7
Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.观察性研究伏立康唑的临床疗效及其与患者血浆浓度的关系。
Antimicrob Agents Chemother. 2011 Oct;55(10):4782-8. doi: 10.1128/AAC.01083-10. Epub 2011 Jul 18.
8
Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.常规治疗药物监测中伏立康唑低浓度的调节剂。
Ther Drug Monit. 2011 Feb;33(1):86-93. doi: 10.1097/FTD.0b013e31820530cd.
9
Impact of therapeutic drug monitoring of voriconazole in a pediatric population.伏立康唑治疗药物监测对儿科人群的影响。
Pediatr Infect Dis J. 2011 Jun;30(6):533-4. doi: 10.1097/INF.0b013e318204d227.
10
Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.伏立康唑：一种广谱三唑类药物，用于治疗侵袭性真菌感染。
Expert Rev Hematol. 2009 Jun;2(3):237-54. doi: 10.1586/ehm.09.13.
Zotero 插件